Masimo | MASI - Gross Profit On Sales


Masimo reported $250.8M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Accuray USD 41.89M 7.42M Dec/2024
Align Technology USD 736.59M 53M Mar/2026
AngioDynamics USD 44.78M 2.93M Sep/2025
Artivion USD 73.14M 1.25M Dec/2025
AtriCure USD 109.31M 3.97M Mar/2026
Avanos Medical USD 94.2M 8.2M Mar/2026
Baxter International USD 891M 314M Mar/2026
Becton, Dickinson and Co. USD 2.15B 257M Mar/2026
Boston Scientific USD 3.61B 64M Mar/2026
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
General Electric Aerospace USD 4.24B 439M Mar/2026
Globus Medical USD 496.26M 39.69M Mar/2026
Haemonetics USD 202.39M 7.64M Dec/2025
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 540.8M 27.8M Mar/2026
Integra LifeSciences USD 213.21M 3.89M Mar/2026
Intuitive Surgical USD 1.83B 73.8M Mar/2026
Masimo USD 250.8M 3.5M Mar/2026
Medtronic USD 6.01B 595M Mar/2026
Orthofix International USD 153.28M 4.76M Dec/2025
Owens Minor USD 272.05M 20.92M Dec/2025
ResMed USD 890.98M 12.26M Mar/2026
Steris USD 655.5M 9.6M Dec/2025
Stryker USD 3.81B 675M Mar/2026
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.43M 21K Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025